These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33209615)

  • 1. Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib.
    Wang Y; He Y; Tian P; Wang W; Wang K; Chuai S; Li Y; Zhao S; Wang Y; Li W
    Transl Lung Cancer Res; 2020 Oct; 9(5):1952-1962. PubMed ID: 33209615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma pre-treatment T790M relative allelic frequency in patients with advanced EGFR-mutated non-small cell lung cancer predicts treatment response to subsequent-line osimertinib.
    Ding PN; Roberts TL; Chua W; Becker TM; Caixeiro N; de Souza P; Gao B; Lee CK; Itchins M; Westman H; Clarke S; Blinman P; Kao S; John T; Leal JL; Bray VJ
    Transl Lung Cancer Res; 2021 Apr; 10(4):1623-1634. PubMed ID: 34012779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy.
    Fu Y; Wang A; Zhou J; Feng W; Shi M; Xu X; Zhao H; Cai L; Feng J; Lv X; Zhang X; Xu W; Zhang Z; Ma G; Wang J; Zhou T; Zhao D; Fang H; Liu Z; Huang JA
    Front Oncol; 2021; 11():621992. PubMed ID: 33718183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of genomic alternations in epidermal growth factor receptor (EGFR)-T790M-mutated non-small cell lung cancer (NSCLC) patients with acquired resistance to osimertinib therapy.
    Hsu PC; Chang JW; Chiu LC; Yang CT; Kuo SC; Fang YF; Wu CE
    Clin Transl Oncol; 2024 Sep; ():. PubMed ID: 39317868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
    Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
    Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation.
    Joshi A; Butle A; Hait S; Mishra R; Trivedi V; Thorat R; Choughule A; Noronha V; Prabhash K; Dutt A
    Transl Oncol; 2022 Aug; 22():101461. PubMed ID: 35653897
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Zheng Q; Huang Y; Zhao H; Yang Y; Hong S; Hou X; Zhao Y; Ma Y; Zhou T; Zhang Y; Fang W; Zhang L
    Transl Lung Cancer Res; 2020 Jun; 9(3):471-483. PubMed ID: 32676311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
    Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P
    Lung Cancer; 2019 Aug; 134():72-78. PubMed ID: 31319999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer.
    Pan G; Chen K; Yu X; Sheng J; Fan Y
    Transl Cancer Res; 2021 Jun; 10(6):2895-2905. PubMed ID: 35116599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
    Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
    Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.
    Zhang Y; Chen HM; Liu YM; Peng F; Yu M; Wang WY; Xu H; Wang YS; Lu Y
    World J Clin Cases; 2019 May; 7(10):1221-1229. PubMed ID: 31183356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib.
    Romero A; Serna-Blasco R; Alfaro C; Sánchez-Herrero E; Barquín M; Turpin MC; Chico S; Sanz-Moreno S; Rodrigez-Festa A; Laza-Briviesca R; Cruz-Bermudez A; Calvo V; Royuela A; Provencio M
    Transl Lung Cancer Res; 2020 Jun; 9(3):532-540. PubMed ID: 32676317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of different methods for detecting T790M mutation in the plasma of patients with advanced NSCLC after developing resistance to first-generation EGFR-TKIs in a real-world clinical setting.
    Hou T; Zeng J; Xu H; Su S; Ye J; Li Y
    Mol Clin Oncol; 2022 Apr; 16(4):88. PubMed ID: 35251639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (
    Xu Z; Hao X; Wang Q; Wang J; Yang K; Wang S; Teng F; Li J; Xing P
    Cancer Manag Res; 2022; 14():863-873. PubMed ID: 35256860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The emergence of various genetic alterations mediated the Osimertinib resistance of a patient harboring heterozygous germline EGFR T790M: a case report.
    Liu B; Qin J; Yin Y; Zhai L; Liu G; Lizaso A; Shi D
    Ann Transl Med; 2021 Jan; 9(1):80. PubMed ID: 33553373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.
    Santarpia M; Liguori A; Karachaliou N; Gonzalez-Cao M; Daffinà MG; D'Aveni A; Marabello G; Altavilla G; Rosell R
    Lung Cancer (Auckl); 2017; 8():109-125. PubMed ID: 28860885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real-world clinical example.
    Wei B; Zhao C; Li J; Zhao J; Ren P; Yang K; Yan C; Sun R; Ma J; Guo Y
    Mol Oncol; 2019 May; 13(5):1226-1234. PubMed ID: 30927306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome.
    Vendrell JA; Quantin X; Aussel A; Solassol I; Serre I; Solassol J
    Transl Lung Cancer Res; 2021 Nov; 10(11):4084-4094. PubMed ID: 35004240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial.
    Zhang YC; Chen ZH; Zhang XC; Xu CR; Yan HH; Xie Z; Chuai SK; Ye JY; Han-Zhang H; Zhang Z; Bai XY; Su J; Gan B; Yang JJ; Li WF; Tang W; Luo FR; Xu X; Wu YL; Zhou Q
    EBioMedicine; 2019 May; 43():180-187. PubMed ID: 31027916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M-positive lung cancer after osimertinib.
    Kato R; Hayashi H; Sakai K; Suzuki S; Haratani K; Takahama T; Tanizaki J; Nonagase Y; Tanaka K; Yoshida T; Takeda M; Yonesaka K; Kaneda H; Nishio K; Nakagawa K
    Int J Clin Oncol; 2021 Sep; 26(9):1628-1639. PubMed ID: 34117553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.